4 years ago

Reacta Biotech Secures £2.9 Million to Expand Food Allergy Diagnostics

  • Reacta Biotech, a UK-based food allergy diagnostic company, has raised £2.9 million in funding

  • The round was led by Praetura Ventures with participation from existing shareholders including the Development Bank of Wales, Perscitus, Jon Moulton’s family office, and Reacta’s management team

  • The company intends to use the funds to scale up manufacturing, expand its product portfolio, grow its team, and accelerate packaging solutions

  • The investment follows a series of growth milestones for Reacta Biotech, including a multimillion-pound commercial contract with a top five global pharmaceutical company and MHRA approval for its manufacturing facility.

      • ProblemHealthcare

      "Diagnosing food allergies is a lengthy and complex process, often involving multiple tests and visits to specialists. This can be stressful and inconvenient for patients, and it can also lead to misdiagnosis or delayed treatment. Existing methods are often inaccurate, leading to unnecessary anxiety and discomfort for patients."

      Solution

      "Reacta Biotech has developed a range of clinical diagnostics kits for food allergy testing. These kits are based on Oral Food Challenges (OFCs), the gold standard test for diagnosing food allergies. OFCs are a safe and effective way to diagnose food allergies, and Reacta Biotech's kits are designed to improve the efficiency, accuracy and safety of OFC testing."

      Covered on